Functional blepharoplasty and visual fields

What counts as functional

• A Medicare Local Coverage Determination for blepharoplasty, blepharoptosis repair and brow procedures states that surgery performed "for the sole purpose of improving appearances" is not medically reasonable and necessary (LCD L34028).
• The American Academy of Ophthalmology's 2011 evidence report reviewed 13 studies on simulated ptosis, ptosis repair and blepharoplasty; it named MRD1 of 2mm or less, superior visual field loss of at least 12 degrees or 24%, down-gaze impairment of reading, a chin-up head tilt, discomfort, and central visual interference as preoperative indicators of surgical improvement (PMID 22019388).
• Medicare's coding article lists a 12- to 15-degree superior field loss or 24%-30% superior visual field impairment, an MRD1 of 2mm or less, or a palpebral fissure height in down-gaze of 1mm or less as documentation supporting medical necessity (CMS A57025).
• A 2024 review of 70 US insurance policies found 67 (96%) cover blepharoplasty for at least one functional indication: dermatochalasis with visual field loss (56 of 70, 80%), anophthalmic-socket prosthesis difficulty (44, 63%) and congenital ptosis (38, 54%) were the three most common (PMID 39258929).
• Of the policies that required visual field testing for dermatochalasis (95% of those covering it), significantly more set the bar at a 30% superior field loss than at the 24% figure more often cited in the literature (14 of 70 policies against 3, 26% against 6%, P=0.0067) (PMID 39258929).
• Eyelid skin can itself produce visual field defects that mimic unrelated disease: dermatochalasis produced apparent bitemporal hemianopsia on Humphrey testing in 3 patients, one of whom underwent a brain MRI before taping the lid and repeating the test resolved the defect (PMID 12644764); it produced apparent glaucomatous field defects in 9 ocular-hypertensive patients (18 eyes), confirmed by taping and by blepharoplasty in 2 cases (PMID 9474318).

How eligibility is tested

• The method traces to automated static perimetry of simulated ptosis in 20 volunteers, where even mild eyelid loading significantly depressed the superior meridian (P<0.01) (PMID 8493006); an earlier series in blepharochalasis and ptosis patients found the degree of ptosis correlated with the size of the field defect (PMID 7609399). The standard test compares the visual field with the eyelid untaped against the field with the lid taped or manually elevated to simulate the postoperative position; the difference defines the deficit (PMID 10636416).
• 12 patients, bilateral ptosis: Goldmann (manual kinetic) testing took 10±2 minutes against 50±10 minutes for Humphrey (automated static) testing (P<.001); Goldmann detected 18±9 degrees of taped-minus-untaped loss against 14±13 degrees on Humphrey (P<.04) (PMID 10636416).
• 20 patients: Goldmann took 6.4 minutes less than Humphrey (95% CI 4.5-8.3, P<0.001) and was preferred by 70% of patients, with no difference between the two in detecting superior field loss (PMID 23924985).
• Tangent screen testing correlated with margin-to-reflex distance (r=0.87) and used the cheapest equipment of the options compared (PMID 28355310). A modified peripheral field test, validated in 194 eyes, detected ptosis with 98.8% sensitivity and tracked surgical improvement (PMID 21252946).
• A disposable field-test device was compared with Goldmann, Humphrey and tangent screen in 40 patients: Goldmann detected a 30%-or-greater superior field occlusion in 98% of eyes against 73% for the novel device, 55% for Humphrey and 50% for tangent screen (PMID 39840757).
• VR field testing on a consumer headset agreed with standard automated perimetry on the 30% insurance-coverage criterion in 71.8%-82.1% of eyes (PMID 36852832); a separate VR hemifield algorithm showed 83.3% agreement with Humphrey testing on the same threshold (PMID 36282119). The 2023 VR pilot study drew a published comment on its methods and a reply from its authors (PMID 38967570), (PMID 38967571).
• A 2026 trial compared taping with phenylephrine 2.5% drops in 27 ptotic eyes: the 12-degree insurance criterion was met in 88.8% of eyes with taping and 92.5% with phenylephrine (P=1.000, not significant); MRD1 rose a mean 1.33mm with phenylephrine, and satisfaction scored higher with drops than tape (4.26±0.81 against 3.67±0.48, P<0.001) (PMID 42024579).
• Medicare's photo guidance calls for frontal shots, canthus to canthus, head perpendicular to the camera; oblique photos are required only when lash-overhanging skin is the sole indication, and photos with the lid skin retracted are required when redundant skin coexists with true ptosis (CMS A57025).
• CPT 15822 covers upper-eyelid blepharoplasty; CPT 15823 adds that excess skin is weighing down the lid, the code used when the criteria above are met (Pabau CPT 15822/15823). CPT 67904 covers blepharoptosis repair by tarsal and levator resection or advancement through an external incision; CPT 67908 covers repair by conjunctiva-tarsus-Müller's-muscle-levator resection, the Fasanella-Servat type (AAPC 67904), (AAPC 67908). Medicare does not pay separately for a blepharoplasty code and a ptosis-repair code on the same eyelid in the same session (CMS A57025).

Results and evidence

• The AAO's 13-study evidence review concluded repair of blepharoptosis and dermatochalasis provides significant improvement in vision, peripheral vision and quality-of-life activities (PMID 22019388).
• 100 patients: the functional-index score rose a mean 30 points after repair (P<0.001); the strongest predictor of improvement was preoperative self-reported functional impairment (r=-0.79, P<0.001), not the manually-taped preoperative field test (P>0.100) (PMID 10485538); a companion editorial framed the finding as a tension between clinical evidence and insurer criteria (PMID 10485528).
• 90 eyelids meeting Danish national visitation guidelines: mean upper visual field improvement was 31.3 percentage points (right) and 28.3 (left), correlating with the preoperative eyelid-to-visual-axis distance (PMID 28205342).
• 46 eyelids: preoperative untaped Goldmann testing underestimated the eventual postoperative gain in 76% of cases by a mean 61%, and overestimated it in 24% of cases by a mean 23% (PMID 28812936).
• 18 eyelids: blepharoplasty produced an average 4.99-fold gain in the superior visual field; the preoperative field predicted the outcome (P=0.001) while preoperative MRD1 did not (P=0.119) (PMID 35086303).
• 78 eyes: contrast sensitivity gains predicted by preoperative taped testing (11.85% increase) closely matched the actual postoperative gain (11.44%, P=0.864 between the two); MRD1 improved a mean 2.0mm (P<0.0005) (PMID 25216198).
• 80 eyes: mean visible field area rose from 46.20 preoperatively to 56.73 at 1 month and 65.96 at 3 months, significant at each interval (PMID 38447291); 32 patients: MRD1, corneal exposure area, brow height and corneal astigmatism axis all improved significantly by 3 months (PMID 39392642).
• Systematic review of 28 studies: enlarged visual field and improved headache- and vision-related quality of life were consistently reported; eyebrow height, astigmatism, contrast sensitivity and eyelid kinematics results were inconsistent (PMID 30528286).
• AAO's 2025 review of 20 validated-instrument studies: 5 of 7 dry-eye studies found no subjective worsening; 3 studies of ptosis correction found quality-of-life benefit continued at 1.5 to 3.6 years (PMID 40913605).
• 108 blepharoplasty and 44 ptosis-repair patients with tension headache: Headache Impact Test-6 scores improved in both groups (blepharoplasty 55.9 to 46.4; ptosis repair 60.0 to 42.3, P=0.001 each), more after levator resection than Müller's muscle resection or frontalis suspension (PMID 28253391).
• 55 patients: the NEI Visual Functioning Questionnaire-25 score rose significantly after ptosis surgery (P<0.001), with gains in near/peripheral vision, color vision, ocular pain, dependence and mental health (PMID 40343557).
• 210 raters scoring before/after photos on 11 personal-characteristic scales: postoperative photos scored better on all 11 (P<.01 to P<.001) (PMID 11797321).
• 50 patients, 27-item questionnaire: 67% of unilateral and 75% of bilateral cases improved on vision-related items after repair; the four most-improved activities were fine manual work, reaching above eye level, television and reading (PMID 8644811).

Risks and complications

• Insurance criteria vary enough to change who qualifies: across 70 reviewed US policies, the required superior-field-loss threshold for dermatochalasis coverage ranged from 24% to 30%, more choosing the stricter figure than the literature-supported one (PMID 39258929).
• A test performed to establish eligibility can itself work against a patient: preoperative Goldmann testing underestimated the eventual postoperative gain in 76% of 46 eyelids (PMID 28812936).
• Dermatochalasis can produce field defects that mimic unrelated disease on tests ordered for other reasons, including apparent bitemporal hemianopsia (PMID 12644764) and apparent glaucomatous loss (PMID 9474318); see "What counts as functional" above.
• Surgical risks of the operations themselves (orbital hemorrhage, dry eye, lagophthalmos, wound dehiscence, revision) are reported by procedure in upper-blepharoplasty.md and blepharoptosis-repair.md and are not repeated here.

Combined procedures

• Since October 1, 2017, Medicare has allowed payment for a medically necessary blepharoptosis repair performed together with a non-covered cosmetic blepharoplasty on the same eye at the same visit (CMS A57025).
• Medicare does not pay separately for a blepharoplasty code (15822/15823) and a ptosis-repair code (67901-67908) on the same eyelid at the same session; each procedure's medical-necessity criteria must be documented individually, and two sets of photographs are required when both are planned (CMS A57025).
• Hering's law, the equal nerve drive to both upper eyelids, can be cited in Medicare documentation to support bilateral ptosis-repair coverage when only one eyelid independently meets the numeric criteria and the fellow lid's ptosis becomes apparent once the first is corrected (CMS A57025).
• Brow ptosis repair is evaluated under its own functional criteria in the same Medicare coverage policy (CMS LCD L34028); see temporal-and-lateral-brow-lift.md and browpexy-and-direct-brow-lift.md for the operative literature.
• Eight CPT codes (15820-15823, 67900-67908) require prior authorization when performed in an ambulatory surgical center or hospital outpatient department under Medicare's program, with cosmetic-only surgery excluded from payment regardless of authorization (FCSO prior-authorization program).

Current questions

• Insurance criteria are not standardized: reviewed US commercial policies set superior-field-loss thresholds from 24% to 30%, more often choosing the stricter figure even though the literature more often supports 24% (PMID 39258929).
• A 2026 narrative review argues visual field restriction, while an important indication for publicly funded upper blepharoplasty, does not capture the full disease burden of dermatochalasis, and that no validated dermatochalasis-specific symptom questionnaire yet exists (PMID 42693598).
• Whether newer field-testing technology, including VR headsets and disposable single-use devices, can substitute for standard automated or Goldmann perimetry in insurance determinations remains under study; the 2023 VR pilot study prompted a published methodological exchange between clinicians (PMID 36852832), (PMID 38967570), (PMID 38967571).
• Phenylephrine drops produced statistically equivalent pass rates on the 12-degree insurance criterion compared with manual taping, with higher patient satisfaction, in a 2026 trial, raising the question of whether taping is still necessary for every preoperative evaluation (PMID 42024579).
• Glaucoma visual field technicians commonly tape patients with visually obstructive eyelids before glaucoma perimetry; a 2024 study of 60 eyes found no spurious field abnormality among reliably tested glaucoma patients who were not flagged for taping, which the authors argue makes an unreliable (rather than falsely abnormal) field test the more relevant sign of eyelid interference (PMID 38406664).
• A 2025 review written for otolaryngologists states plainly that oculoplastic surgeons use visual field testing to document eyelid- and brow-related vision loss "for insurance purposes," underscoring that the test's clinical and administrative functions are intertwined in US practice (PMID 40268625).

Terms

• MRD1 (margin reflex distance 1): distance from the corneal light reflex to the upper eyelid margin; 2mm or less is a common insurance threshold (PMID 22019388). A 28-study analysis found the mean MRD1 gain after ptosis surgery was 2.15mm and varied by technique (frontalis suspension 2.4mm, aponeurotic surgery 2.3mm, Müller's muscle resection 2.0mm, levator resection 1.8mm) (PMID 26967079).
• Superior visual field loss: reduction in the upper field of vision caused by eyelid or brow position, measured in degrees or percent of points seen (PMID 10636416).
• Taped (or manually elevated) visual field test: the eyelid held in a simulated postoperative position during perimetry, compared with the same test performed with the lid in its natural, untaped position, to estimate surgical benefit (PMID 10636416).
• Goldmann perimetry: manual kinetic visual field testing; Humphrey perimetry: automated static visual field testing; the two are compared directly for test time and sensitivity in ptosis field studies (PMID 23924985).
• Palpebral fissure height in down-gaze: the eyelid opening measured with the patient looking down and the brow relaxed; 1mm or less is a Medicare documentation criterion (CMS A57025).
• Hering's law: equal nerve drive to both upper eyelids, used in Medicare documentation to justify bilateral ptosis-repair coverage when only one eyelid meets the numeric criteria on its own (CMS A57025).
• Pseudoptosis: an eyelid margin that appears low because of overhanging skin rather than true levator or Müller's muscle weakness (PMID 35086303).
• CPT 15822/15823: procedure codes for upper-eyelid blepharoplasty; 15823 denotes excess skin weighing down the lid (CMS A57025).
• CPT 67904/67908: procedure codes for blepharoptosis repair; 67904 is external levator resection or advancement, 67908 is conjunctiva-tarsus-Müller's-muscle-levator resection (AAPC 67904), (AAPC 67908).
• LCD (Local Coverage Determination): a Medicare contractor's written coverage policy, such as L34028 for blepharoplasty and ptosis repair (CMS LCD L34028).

Papers